IDIS, a UK firm that develops and implements the pre-launch of named patient programs, is opening a new regional office in Iselin, New Jersey, USA. The new base will assist US drugmakers in the implementation of programs to support early access of their medicines.
NPPs provide drug developers with a legal and ethical way to make medicines available where appropriate, in response to requests made by physicians, even when those products are not yet approved in their country or are still in late-stage clinical trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze